tm logo
LEZFERZI
REGISTERED

on 25 Jan 2023

Last Applicant/ Owned by

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Binger Straße 17355218 Ingelheim

DE

Serial Number

2087130 filed on 01st Dec 2020

Registration Number

TMA1162647 registered on 25th Jan 2023

Registration expiry Date

01st Dec 2030

Correspondent Address

33 Yonge Street, Suite 300Toronto

ONTARIO

CA

M5E1G4

LEZFERZI

Trademark usage description

pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system disea Read More

Classification Information


Class [005]
Pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of neurological diseases and disorders, namely brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of musculoskeletal diseases and disorders, namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of sexual dysfunction; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of migraines; pharmaceutical preparations for the treatment of pain, namely headaches, migraines, back pain, pain from burns, neuropathic pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of immunological diseases and disorders, namely autoimmune diseases, immunologic deficiency syndromes, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for the treatment of viral diseases and disorders, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely mood disorders, anxiety disorders, panic disorders, cognitive disorders, schizophrenia, depression; pharmaceutical preparations for the treatment of substance abuse disorders, namely alcoholism and drug addiction; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of prostate disorders; pharmaceutical preparations for the treatment of pulmonary disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the treatment of gynecological disorders, namely premenstrual syndrome, endometreosis, yeast infections, menstrual irregularities; pharmaceutical preparations, namely cholesterol preparations, namely preparations to lower cholesterol; pharmaceutical preparations namely smoking cessation preparations; pharmaceutical preparations for the treatment of damaged skin and tissues, namely, rashes, sores, psoriasis, eczema; pharmaceutical preparations namely acne medication; pharmaceutical preparations namely allergy medication; pharmaceutical preparations namely antacids; pharmaceutical preparations namely anthelmintics; pharmaceutical preparations namely antiarrhythmics; pharmaceutical preparations namely antibiotics; pharmaceutical preparations namely anticoagulants; pharmaceutical preparations namely anticonvulsants; pharmaceutical preparations namely antidepressants; pharmaceutical preparations namely antiemetics; pharmaceutical preparations namely antiflatulants; pharmaceutical preparations namely antihistamines; pharmaceutical preparations namely antihypertensives; pharmaceutical preparations namely anti-infectives; pharmaceutical preparations namely anti-inflammatories; pharmaceutical preparations namely antiparasitics; pharmaceutical preparations namely antibacterials; pharmaceutical preparations namely antifungals; pharmaceutical preparations namely antivirals; pharmaceutical preparations namely burn relief medication; pharmaceutical preparations namely calcium channel blockers; pharmaceutical preparations namely central nervous system depressants; pharmaceutical preparations namely central nervous system stimulants; pharmaceutical preparations namely cough treatment medication; pharmaceutical preparations namely diarrhea medication; pharmaceutical preparations namely gastrointestinal medication; pharmaceutical preparations namely glaucoma agents; pharmaceutical preparations namely hydrocortisone; pharmaceutical preparations namely hypnotic agents; pharmaceutical preparations namely sedatives.


Classification kind code

11

Mark Details


Serial Number

2087130

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 48
on 28th Sep 2022
Agent Changed
Submitted for opposition 22
on 06th Jun 2022
Search Recorded
Submitted for opposition 20
on 06th Jun 2022
Examiner's First Report
Submitted for opposition 223
on 06th Jun 2022
Total Provisional Refusal
Submitted for opposition 256
on 27th Dec 2021
Notification of Possible Opposition Sent
Submitted for opposition 257
on 25th Feb 2021
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 24th Feb 2021
Created
Submitted for opposition 31
on 24th Feb 2021
Formalized
Submitted for opposition 228
on 01st Dec 2020
International Registration
Submitted for opposition 30
on 01st Dec 2020
Filed